EVO301: an IL18BP-SAFA biologic demonstrates prolonged residence in inflamed skin and efficacy in a preclinical atopic dermatitis model

Evommune Inc. published this content on November 09, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on April 03, 2026 at 22:01 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]